CN102416129A - Chinese medicine for treating paracmastic chronic obstructive pulmonary disease - Google Patents
Chinese medicine for treating paracmastic chronic obstructive pulmonary disease Download PDFInfo
- Publication number
- CN102416129A CN102416129A CN2011103973269A CN201110397326A CN102416129A CN 102416129 A CN102416129 A CN 102416129A CN 2011103973269 A CN2011103973269 A CN 2011103973269A CN 201110397326 A CN201110397326 A CN 201110397326A CN 102416129 A CN102416129 A CN 102416129A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- chronic obstructive
- obstructive pulmonary
- pulmonary disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicine for treating paracmastic chronic obstructive pulmonary disease. The Chinese medicine comprises the following raw materials in part by weight: 4 to 10 parts of Chinese magnoliavine fruit, 2 to 7 parts of largehead atractylodes rhizome, 2 to 7 parts of tuckahoe, 4 to 10 parts of epimedium, 6 to 14 parts of astragalus, 5 to 12 parts of tokay, 2 to 7 parts of sappan wood, 2 to 7 parts of peach seed, 4 to 10 parts of earthworm, 2 to 7 parts of bitter apricot seed, 4 to 10 parts of sessile stemona root, 2 to 7 parts of heartleaf houttuynia herb, 2 to 7 parts of unibract fritillary bulb, 2 to 7 parts of thinleaf milkwort root-bark, 2 to 7 parts of white mulberry root-bark, 2 to 7 parts of dwarf lilyturf tuber, 2 to 7 parts of cicada slough, 2 to 7 parts of liquoric root, 2 to 7 parts of cinnamomvine and 2 to 7 parts of common coltsfoot flower. The Chinese medicine for treating paracmastic chronic obstructive pulmonary disease has a scientific and reasonable formula, and a preparation method is simple and easy to control, so the Chinese medicine has the advantages of high cure rate, relapse prevention and no toxic or side effect in the aspect of treating paracmastic chronic obstructive pulmonary disease.
Description
Technical field
The present invention relates to a kind of Chinese medicine that is used to treat the catabasis chronic obstructive pulmonary disease.
Background technology
Chronic obstructive pulmonary disease be one group with incomplete reversibility airflow obstruction and carry out the chronic respiratory system diseases that sexual development is a characteristic.This disease be chronic evolution very easily repeatedly, the delay refractory, custom has saying of " interior not controlling being breathed heavily ".Primary disease always belongs to deficiency in origin and excess in superficiality, and the sense heresy is the domination of pathogen partially then, at ordinary times deficiency in origin then.The domination of pathogen shows as the stagnation of QI, phlegm-damp, blood stasis, edema and mixed for suffering from.The dificiency of the lung due to protracted disease influences spleen, kidney, the heart then.Be yang deficiency or deficiency of both YIN and YANG behind the deficiency of vital energy or the deficiency of both QI and YIN just.Its cause of disease is complicated, is commonly encountered diseases in the world wide, frequently-occurring disease, does not still have specific drug at present, and is most with antiinflammatory, antitussive treatment, but poor effect, easy relapse.
Summary of the invention
The present invention is directed to the above-mentioned deficiency that existing treatment catabasis chronic obstructive pulmonary disease exists, a kind of Chinese medicine that is used to treat the catabasis chronic obstructive pulmonary disease is provided.
The technical scheme that the present invention solves the problems of the technologies described above is following: a kind of raw material and parts by weight thereof that are used to treat the Chinese medicine of catabasis chronic obstructive pulmonary disease comprise: 4～10 parts of Fructus Schisandrae Chinensis; 2～7 parts of the Rhizoma Atractylodis Macrocephalaes; 2～7 parts in Poria; 4～10 parts of Herba Epimedii; 6～14 parts of the Radixs Astragali; 5～12 parts of Geckos; 2～7 parts of Lignum Sappans; 2～7 parts in Semen Persicae; 4～10 parts of Pheretimas; 2～7 parts of Semen Armeniacae Amarums; 4～10 parts of the Radixs Stemonae; 2～7 parts of Herba Houttuyniae; 2～7 parts of Bulbus Fritillariae Cirrhosaes; 2～7 parts of Radix Polygalaes; 2～7 parts of Cortex Mori; 2～7 parts of Radix Ophiopogonis; 2～7 parts of Periostracum Cicadaes; 2～7 parts in Radix Glycyrrhizae; 2～7 parts of 2～7 parts of Rhizoma Dioscoreaes and Flos Farfaraees.
On the basis of technique scheme, the present invention can also do following improvement.
Further, the raw material of said Chinese medicine and parts by weight thereof comprise: 2～5 parts of 4～8 parts of Fructus Schisandrae Chinensis, 2～5 parts of the Rhizoma Atractylodis Macrocephalaes, 2～5 parts in Poria, 4～8 parts of Herba Epimedii, 6～11 parts of the Radixs Astragali, 5～9 parts of Geckos, 2～5 parts of Lignum Sappans, 2～5 parts in Semen Persicae, 4～8 parts of Pheretimas, 2～5 parts of Semen Armeniacae Amarums, 4～8 parts of the Radixs Stemonae, 2～5 parts of Herba Houttuyniae, 2～5 parts of Bulbus Fritillariae Cirrhosaes, 2～5 parts of Radix Polygalaes, 2～5 parts of Cortex Mori, 2～5 parts of Radix Ophiopogonis, 2～5 parts of Periostracum Cicadaes, 2～5 parts in Radix Glycyrrhizae, 2～5 parts of Rhizoma Dioscoreaes and Flos Farfaraees.
Further, the raw material of said Chinese medicine and parts by weight thereof comprise: 4 parts of 5 parts of Fructus Schisandrae Chinensis, 4 parts of the Rhizoma Atractylodis Macrocephalaes, 4 parts in Poria, 5 parts of Herba Epimedii, 8 parts of the Radixs Astragali, 6 parts of Geckos, 4 parts of Lignum Sappans, 4 parts in Semen Persicae, 5 parts of Pheretimas, 4 parts of Semen Armeniacae Amarums, 5 parts of the Radixs Stemonae, 4 parts of Herba Houttuyniae, 4 parts of Bulbus Fritillariae Cirrhosaes, 4 parts of Radix Polygalaes, 4 parts of Cortex Mori, 4 parts of Radix Ophiopogonis, 4 parts of Periostracum Cicadaes, 4 parts in Radix Glycyrrhizae, 4 parts of Rhizoma Dioscoreaes and Flos Farfaraees.
The invention has the beneficial effects as follows: the present invention be used to treat the Chinese medicine preparation science of catabasis chronic obstructive pulmonary disease, rationally, method for preparing is simple and control treatment easily; Aspect treatment catabasis chronic obstructive pulmonary disease, the advantage that have the cure rate height, is difficult for recurrence, has no side effect.
The specific embodiment
Below principle of the present invention and characteristic are described, institute gives an actual example and only is used to explain the present invention, is not to be used to limit scope of the present invention.
COPD (chronic obstructive pulmonary diseases; The abbreviation chronic obstructive pulmonary disease) the cause of disease is not illustrated at present as yet fully; But the sickness rate of many factors and primary disease increases certain relation is arranged; It is that environmental factors comprises the smoking respiratory tract infection that these risk factors can be divided into exopathogenic factor, professional dust and chemical substance; The promptly individual trouble factor that is prone to of endogenous cause of ill comprises respiratory tract local defense and immunologic function attenuating, autonomic nervous dysfunction, airway hyper-reaction, lung development undergrowth etc.The prolonged and repeated effect of internal and external factor causes the bronchospasm edema, and mucus secretion increases, pulmonary alveolar overdistension, lung arteriolospasm, and pulmonary circulation a series of pathological changes and carrying out property such as be obstructed increases the weight of.Motherland's medical science thinks that lung governing qi department breathes, and lung being a delicate viscus is subject to the exopathogen invasion and attack, and the damage lung conductance causes that mistake department falls in a surname and a cough with asthma.Pneumonopathy and spleen child-organ disease involving its motherorgan, then dysfunction of the spleen in transportation expectorant is turbid interior living, and failure of the kidney in receiving QI is moving then to be breathed heavily very.The primary disease catabasis is mainly lung, spleen, deficiency of kidney-QI, and visceral dysfunction is main, and the Chinese medicine that is used to treat the catabasis chronic obstructive pulmonary disease of warp research invention for many years focuses on and transfers tonifying the lung, spleen, kidney to ill mechanism.Dialectical with the internal organs QI and blood, negative and positive are deficient to be main, stresses the medication of the side of choosing, and wherein the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Poria, Gecko, Pheretima have the benefiting QI for strengthening the superficies spleen invigorating, and the merit that improving inspiration by invigorating the kidney is relievingd asthma is monarch drug altogether; Fructus Schisandrae Chinensis, Herba Epimedii, Rhizoma Dioscoreae, Bulbus Fritillariae Cirrhosae, the Radix Stemonae, Periostracum Cicadae, the merit with dispersing lung-QI and dissipating phlegm, relieving cough and asthma, reinforcing the kidney and supporting YANG are ministerial drug altogether; The merit that has Semen Persicae, Lignum Sappan, Semen Armeniacae Amarum, Flos Farfarae, Cortex Mori, Herba Houttuyniae, Radix Polygalae, Radix Ophiopogonis relieving cough and resolving phlegm blood stasis dispelling, lung moistening relieving constipation dispersing and lowering lung-QI is adjuvant drug altogether; The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription is a messenger drug.More than all medicines play the spleen invigorating lung benefiting jointly, improving inspiration by invigorating the kidney, dispersing lung-QI and dissipating phlegm, the effect of relieving cough and asthma.This is main double eliminating evil for setting upright, eliminating evil justice of just not hindering.
Clinical report:
1, physical data:
Case 200 examples are Xianghe County asthma section of tracheitis, asthma hospital inpatient, adopt the randomized, double-blind principle to be divided into 2 groups.100 examples are organized in treatment, male 49 examples, women 51 examples; 20～63 years old age, average (43.2 ± 7.4) year; The course of disease 5.3～30 years, average (8.6～4.8) year.Matched group 100 examples, male 47 examples, women 53 examples; 19～62 years old age, average (43.1 ± 9.2) year; The course of disease 5.8～27 years, average (9.6 ± 4.7) year.2 groups of physical data comparing difference not statistically significants (p＞0.05) have comparability.
2, diagnostic criteria:
Western medicine diagnose reference " diagnostic criteria of WS 318-2010 chronic obstructive pulmonary disease " tcm diagnosis and differentiation of symptoms and signs for classification of syndrome are with reference to State Administration of Traditional Chinese Medicine " disease of tcm diagnosis criterion of therapeutical effect ".
2.1, include standard in:
Meet diagnosis; 18 years old～65 years old age; The course of disease 4～30 years; Inpatient; I know the inside story
2.2, observation index:
The symptom scalar quantization standard of listing with reference to 2002 " new Chinese medicine clinical research guideline " [4]; In conjunction with every of being seen symptom in clinical (cough, expectoration, laryngeal stridor, breathe heavily and suppress) by light, in, 2 minutes heavily respectively, 4 minutes, 6 minutes; Every of inferior disease (appetite, bitter taste, constipation, breathe hard) by light, in, 1 minute heavily respectively, 3 minutes, 5 minutes; Before and after the treatment item by item inquiry observe, calculate also record total mark, observed and recorded picture of the tongue, pulse condition but do not score.
2.3, criterion of therapeutical effect:
With reference to the disease curative effect determinate standard in " new Chinese medicine clinical research guideline ".Produce effects: original symptom complete obiteration or significantly alleviate, symptom integral reduces >=70%; Effectively: original symptom takes a turn for the better to some extent or alleviates, symptom integral reduce >=30% but＜70%; Invalid: original symptom does not have improvement, symptom integral＜30%.
3, result:
Two groups of Comparison of therapeutic
The result shows: produce effects 72 examples, effective 16 examples, invalid 12 examples, total effective rate 88.0%.
4, model case:
Embodiment 1:
Above-mentioned raw materials is prepared into hard capsule by " the preparation quality standard JZBZ20090679 of medical institutions of Hebei province's food and medicine Surveillance Authority " prescriptive procedure, uses after the assay was approved.
The king so-and-so, the man, 67 years old, people from Tiantai County, Zhejiang Province suffered from surplus chronic obstructive pulmonary disease companion cough, the expectoration 10 year, increased the weight of to breathe heavily after companion's activity and suppressed 2 years, through conventional western medical treatment, do not feel any better.Come my institute to be in hospital, take 6 of the hard capsules that embodiment 1 processes at every turn, every day 3 times, took continuously 160 days; The two pulmonary respiration changes of tune in treatment back are thick, and dried moist rales disappears, and the trusted subordinate is negative, and two lower limbs edema disappear; Vital capacity is increased to 2000ml by 1500ml, transference cure, not recurrence.
The king so-and-so, the woman, 48 years old, Tianjin Wuqing District people suffered from chronic obstructive pulmonary disease companion cough; Expectoration, breathe heavily after the activity suppress 40 surplus year, increase the weight of first quarter moon, through conventional western medical treatment, do not feel any better; Come my institute to be in hospital, take 6 of the hard capsules that embodiment 1 processes at every turn, took 180 days treatment back transference cure every day 3 times continuously; Two pulmonary respiration changes of tune are thick, and two lower limbs edema disappear, and vital capacity is increased to 1700ml by 800ml, not recurrence.
Embodiment 2:
Above-mentioned raw materials is prepared into hard capsule by " the preparation quality standard JZBZ20090679 of medical institutions of Hebei province's food and medicine Surveillance Authority " prescriptive procedure, uses after the assay was approved.
Hao so-and-so, the man, 58 years old, people from Handan County, Hebei province suffered from surplus the chronic obstructive pulmonary disease 10 year; Frequent dead point infection suppressing panting calming medicine, poor effect comes me institute to be in hospital, and takes 6 of the hard capsules that embodiment 2 processes at every turn; Every day 3 times, took continuously 160 days, treat the recovery from illness course of treatment, not a recurrence.
Embodiment 3:
Above-mentioned raw materials is prepared into hard capsule by " the preparation quality standard JZBZ20090679 of medical institutions of Hebei province's food and medicine Surveillance Authority " prescriptive procedure, uses after the assay was approved.
Liu so-and-so, the man, 49 years old, people from Huanghua, Hebei province suffered from surplus the chronic obstructive pulmonary disease 30 year, through conventional western medical treatment poor effect, comes me institute to be in hospital, and took 6 of the hard capsules that embodiment 3 processes at every turn, took 180 days the recovery from illness of treatment back, recurrence every day 3 times continuously.
Embodiment 4:
Above-mentioned raw materials is prepared into hard capsule by " the preparation quality standard JZBZ20090679 of medical institutions of Hebei province's food and medicine Surveillance Authority " prescriptive procedure, uses after the assay was approved.
The Wang, the man, 50 years old, the Chengde County people of Hebei province suffered from chronic obstructive pulmonary disease more than 20 year; Behind conventional western medical treatment, alleviate, but be prone to recurrence, come me institute to be in hospital, take 6 of the hard capsules that embodiment 4 processes at every turn; Every day 3 times, took the recovery from illness of treatment back, not recurrence continuously 180 days.
The above is merely preferred embodiment of the present invention, and is in order to restriction the present invention, not all within spirit of the present invention and principle, any modification of being done, is equal to replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (3)
1. Chinese medicine that is used to treat the catabasis chronic obstructive pulmonary disease; It is characterized in that its raw material and parts by weight thereof comprise: 2～7 parts of 4～10 parts of Fructus Schisandrae Chinensis, 2～7 parts of the Rhizoma Atractylodis Macrocephalaes, 2～7 parts in Poria, 4～10 parts of Herba Epimedii, 6～14 parts of the Radixs Astragali, 5～12 parts of Geckos, 2～7 parts of Lignum Sappans, 2～7 parts in Semen Persicae, 4～10 parts of Pheretimas, 2～7 parts of Semen Armeniacae Amarums, 4～10 parts of the Radixs Stemonae, 2～7 parts of Herba Houttuyniae, 2～7 parts of Bulbus Fritillariae Cirrhosaes, 2～7 parts of Radix Polygalaes, 2～7 parts of Cortex Mori, 2～7 parts of Radix Ophiopogonis, 2～7 parts of Periostracum Cicadaes, 2～7 parts in Radix Glycyrrhizae, 2～7 parts of Rhizoma Dioscoreaes and Flos Farfaraees.
2. the Chinese medicine that is used to treat the catabasis chronic obstructive pulmonary disease according to claim 1; It is characterized in that its raw material and parts by weight thereof comprise: 2～5 parts of 4～8 parts of Fructus Schisandrae Chinensis, 2～5 parts of the Rhizoma Atractylodis Macrocephalaes, 2～5 parts in Poria, 4～8 parts of Herba Epimedii, 6～11 parts of the Radixs Astragali, 5～9 parts of Geckos, 2～5 parts of Lignum Sappans, 2～5 parts in Semen Persicae, 4～8 parts of Pheretimas, 2～5 parts of Semen Armeniacae Amarums, 4～8 parts of the Radixs Stemonae, 2～5 parts of Herba Houttuyniae, 2～5 parts of Bulbus Fritillariae Cirrhosaes, 2～5 parts of Radix Polygalaes, 2～5 parts of Cortex Mori, 2～5 parts of Radix Ophiopogonis, 2～5 parts of Periostracum Cicadaes, 2～5 parts in Radix Glycyrrhizae, 2～5 parts of Rhizoma Dioscoreaes and Flos Farfaraees.
3. the Chinese medicine that is used to treat the catabasis chronic obstructive pulmonary disease according to claim 2; It is characterized in that its raw material and parts by weight thereof comprise: 4 parts of 5 parts of Fructus Schisandrae Chinensis, 4 parts of the Rhizoma Atractylodis Macrocephalaes, 4 parts in Poria, 5 parts of Herba Epimedii, 8 parts of the Radixs Astragali, 6 parts of Geckos, 4 parts of Lignum Sappans, 4 parts in Semen Persicae, 5 parts of Pheretimas, 4 parts of Semen Armeniacae Amarums, 5 parts of the Radixs Stemonae, 4 parts of Herba Houttuyniae, 4 parts of Bulbus Fritillariae Cirrhosaes, 4 parts of Radix Polygalaes, 4 parts of Cortex Mori, 4 parts of Radix Ophiopogonis, 4 parts of Periostracum Cicadaes, 4 parts in Radix Glycyrrhizae, 4 parts of Rhizoma Dioscoreaes and Flos Farfaraees.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103973269A CN102416129A (en) | 2011-12-02 | 2011-12-02 | Chinese medicine for treating paracmastic chronic obstructive pulmonary disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103973269A CN102416129A (en) | 2011-12-02 | 2011-12-02 | Chinese medicine for treating paracmastic chronic obstructive pulmonary disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102416129A true CN102416129A (en) | 2012-04-18 |
Family
ID=45940930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103973269A Pending CN102416129A (en) | 2011-12-02 | 2011-12-02 | Chinese medicine for treating paracmastic chronic obstructive pulmonary disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102416129A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727738A (en) * | 2012-05-09 | 2012-10-17 | 黄淮学院 | Traditional Chinese medicine composition used for treating chronic obstructive pulmonary disease, and preparation method thereof |
| CN103223103A (en) * | 2013-05-20 | 2013-07-31 | 杜明成 | Medical composition for treating chronic obstructive pulmonary disease |
| CN105727031A (en) * | 2016-03-30 | 2016-07-06 | 赵瑜飞 | Formula of LouBeiZhiJuMuGen decoction for treating chronic obstructive pulmonary disease |
| CN106266864A (en) * | 2016-08-23 | 2017-01-04 | 香河县气管炎哮喘医院 | A kind of Chinese medicinal capsule treating catabasis chronic obstructive pulmonary disease and preparation method |
| CN110496181A (en) * | 2019-08-20 | 2019-11-26 | 李俊雄 | A kind of Chinese medicinal capsule preparation and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1310001A (en) * | 2001-02-19 | 2001-08-29 | 孟庆云 | Combined Chinese and Western medicine for treating chronic bronchitis in catabasis |
-
2011
- 2011-12-02 CN CN2011103973269A patent/CN102416129A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1310001A (en) * | 2001-02-19 | 2001-08-29 | 孟庆云 | Combined Chinese and Western medicine for treating chronic bronchitis in catabasis |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727738A (en) * | 2012-05-09 | 2012-10-17 | 黄淮学院 | Traditional Chinese medicine composition used for treating chronic obstructive pulmonary disease, and preparation method thereof |
| CN103223103A (en) * | 2013-05-20 | 2013-07-31 | 杜明成 | Medical composition for treating chronic obstructive pulmonary disease |
| CN105727031A (en) * | 2016-03-30 | 2016-07-06 | 赵瑜飞 | Formula of LouBeiZhiJuMuGen decoction for treating chronic obstructive pulmonary disease |
| CN106266864A (en) * | 2016-08-23 | 2017-01-04 | 香河县气管炎哮喘医院 | A kind of Chinese medicinal capsule treating catabasis chronic obstructive pulmonary disease and preparation method |
| CN110496181A (en) * | 2019-08-20 | 2019-11-26 | 李俊雄 | A kind of Chinese medicinal capsule preparation and preparation method thereof |
| CN110496181B (en) * | 2019-08-20 | 2021-11-09 | 李俊雄 | Chinese medicinal capsule and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101143176A (en) | Traditional Chinese medicine for treating pneumonia | |
| CN103110730B (en) | Perillaseed-radix scutellariae-almond decoction for treating asthma and preparation method thereof | |
| CN102441129B (en) | Traditional Chinese medicine for treating chronic pulmonary heart disease | |
| CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| CN102416129A (en) | Chinese medicine for treating paracmastic chronic obstructive pulmonary disease | |
| CN101129892A (en) | Traditional Chinese medicine for treating aspiration pneumonia | |
| CN101041049A (en) | Chinese traditional medicine compound took orally for treating chronic bronchitis | |
| CN102441105A (en) | Chinese herbal medicine for treating trachitis and asthma | |
| CN108355113A (en) | A kind of Chinese medicine composition and preparation method thereof for treating cough and asthma flu | |
| CN102872325A (en) | Traditional Chinese medicine for treating children cough | |
| CN102416096B (en) | Traditional Chinese medicine for treating bronchiectasis | |
| CN103142733B (en) | Chinese medicine composition for treating upper respiratory infection | |
| CN101966291A (en) | Chinese herbal medicine syrup for treating acute and chronic bronchitis, pulmonary tuberculosis and pulmonary emphysema | |
| CN101234167B (en) | Chinese medicine for treating bronchial asthma and chronic bronchitis | |
| CN101439146A (en) | Medicament for treating chronic pulmonary heart disease and preparation method thereof | |
| CN104127542B (en) | A kind of pharmaceutical composition for the treatment of children's's repetitive upper respiratory tract infection | |
| CN105920420A (en) | Traditional Chinese medicament for treating pneumonia | |
| CN105596930A (en) | Fermentation microorganism Chinese herb preparation for tracheopathy and preparation method and application of fermentation microorganism Chinese herb | |
| CN102284009B (en) | Chinese medicinal herb syrup for treating acute and chronic bronchitis, tuberculosis and emphysema | |
| CN109793852A (en) | A kind of cough-relieving, resolving sputum and the Chinese medicine composition relievingd asthma | |
| CN103566029B (en) | Pharmaceutical composition for treating respiratory diseases and preparation method and usage thereof | |
| CN102743708B (en) | Cordyceps sinensis and gecko powder for treating emphysema pulmonary heart disease asthma chronic bronchitis | |
| CN101143194A (en) | Traditional Chinese medicine for treating interstitial pneumonia | |
| Luo et al. | Professor Xiaoping Liu's experience in treating adenoid hypertrophy in children | |
| CN104721386B (en) | A kind of Traditional Chinese medicine external patch and preparation method thereof for treating asthenic cold type cough and asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120418 |